isotype control igg  (Bio X Cell)

Journal: Journal of Biomedical Science

Article Title: Unraveling Cathepsin S regulation in interleukin-7-mediated anti-tumor immunity reveals its targeting potential against oral cancer

doi: 10.1186/s12929-025-01154-6

Figure Lengend Snippet: Overexpression of CTSS in HNC tissue is inversely correlated with CD8 + T-cell infiltration. A & B The dot graphs show the mRNA expression levels of CTSS in the head and neck cancer (HNC) datasets from ( A ) TCGA and ( B ) GEO ( GSE6791 ). C The representative photos of the CTSS immunohistochemical (IHC) staining on the HNC tissue array. The dot graphs summarize the quantitative score of each sample by stratification. D & E The representative photos of IHC staining for ( D ) CTSS expression and ( E ) CD8 + T-cell infiltration of the in-house oral cancer (OC) samples were shown (N = 70). The score of each sample is plotted by different parameters on the right panels. F & G The correlation between the IHC staining score of CTSS and CD8 in the in-house OC samples was studied. The results are shown by dot graph plots for ( F ) the entire cohort (N = 70) and ( G ) samples with T1 and T2 Stage (N = 38). H The tumor volume of the subcutaneously-inoculated NHRI-HN1 cell is plotted. Mice were implanted with tumors carrying either sh Ctss or shControl, and were grouped by treatment with αCD8 or IgG antibody (N = 6 for each group). Arrowhead indicates days for antibody administration. I The representative photos of the IHC staining for CTSS and CD8 + T cells for each treatment group

Article Snippet: Antibodies were listed in the following: Polyclonal Armenian rat IgG2 isotype control (10 μg/mice) ( cat# BE0086; BioXcell, Lebanon, NH, USA), Anti-mouse/human IL-7 antibody (αIL-7) (10 μg/mice) ( cat# BE0048; BioXcell), Polyclonal Armenian hamster IgG (100 μg/mice) ( cat# BE0091; BioXcell), αPD-1 (100 μg/mice) ( cat# BE0033-2; BioXcell), Rat IgG1 isotype control, anti-horseradish peroxidase (200 μg/mice) ( cat# BP0088; BioXcell), Anti-mouse CD8b antibody (Lyt3.2) (αCD8) (200 μg/mice) ( cat# BE0223; BioXcell).

Techniques: Over Expression, Expressing, Immunohistochemical staining, Immunohistochemistry

Journal: Journal of Biomedical Science

Article Title: Unraveling Cathepsin S regulation in interleukin-7-mediated anti-tumor immunity reveals its targeting potential against oral cancer

doi: 10.1186/s12929-025-01154-6

Figure Lengend Snippet: CTSS inhibits the CD8 + T-cells infiltration and proliferation by downregulating IL-7. A The expression level of IL-7, IL-10, and MCP1 is plotted in the dot graph by each sample (N = 16 in each group). B The tumor volume of the subcutaneously-inoculated NHRI-HN1 cell is plotted. Mice were implanted with tumors carrying either sh Ctss or shControl, and were grouped by treatment with αIL-7 or IgG antibody (N = 10 for each group). Arrowhead indicates days for antibody administration. C The representative photos of the IHC staining for CTSS, IL-7, and CD8 + T-cells for each treatment group. D Tumor infiltrative leukocytes were isolated and analyzed by FACS, the percentage of CD8 + cells in the target quadrant is plotted in the dot graph by each sample. E The percentage of Ki67 + /CD8 + cells in the target quadrant is plotted in the dot graph by each sample. F The percentage of naïve CD8 + cells, central memory CD8 + cells, effector memory CD8 + cells, and tissue-resident CD8 + cells in the target quadrant is plotted in the dot graph by each sample. G & H Mouse CD8 + T-cells were treated with CM with or without the αIL-7. The CM was obtained from in vitro NHRI-HN1 or MOC-1 that were pretreated with siScramble or si Ctss , or that with co-incubation of the mouse IL-7 recombinant protein (mIL-7). ( G) The result of the WST proliferation test for CD8 + T-cells is shown in the dot-bar graph. ( H ) The indicated scale for CFSE cell proliferation is measured and plotted in the dot-bar graph

Article Snippet: Antibodies were listed in the following: Polyclonal Armenian rat IgG2 isotype control (10 μg/mice) ( cat# BE0086; BioXcell, Lebanon, NH, USA), Anti-mouse/human IL-7 antibody (αIL-7) (10 μg/mice) ( cat# BE0048; BioXcell), Polyclonal Armenian hamster IgG (100 μg/mice) ( cat# BE0091; BioXcell), αPD-1 (100 μg/mice) ( cat# BE0033-2; BioXcell), Rat IgG1 isotype control, anti-horseradish peroxidase (200 μg/mice) ( cat# BP0088; BioXcell), Anti-mouse CD8b antibody (Lyt3.2) (αCD8) (200 μg/mice) ( cat# BE0223; BioXcell).

Techniques: Expressing, Immunohistochemistry, Isolation, In Vitro, Incubation, Recombinant

Journal: Nature Communications

Article Title: Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma

doi: 10.1038/s41467-024-49718-8

Figure Lengend Snippet: a Experimental scheme for the treatment of mice bearing epithelial, mixed, and mesenchymal cSCCs with 200 µg/dose of IgG isotype control, anti-PD-L1, anti-PD-1, anti-CTLA-4, and anti-TIGIT antibodies, and 300 µg/dose of anti-CD8 and anti-NK1.1 antibodies (i.p. three times/week). All treatments started when engrafted tumors reached a volume of 65 mm 3 . b Growth kinetics of IgG control, anti-PD-L1, anti-PD-1, anti-PD-L1 + anti-CD8, and anti-PD-L1 + anti-NK-treated epithelial cSCCs ( n = 10 per group). c – f Percentage of c CD8 + T cells, d NK cells, e GzmB + CD8 + T cells, and f GzmB + NK cells in the indicated epithelial cSCCs ( n = 10 per group). g Growth kinetics of IgG control and anti-CTLA-4-treated epithelial cSCCs ( n = 10 per group). h – k Percentage of h CD8 + T cells, i NK cells, j GzmB + CD8 + T cells, and k GzmB + NK cells in IgG control and anti-CTLA-4-treated epithelial cSCCs ( n = 10 per group). l Growth kinetics of IgG control and anti-TIGIT-treated epithelial cSCCs ( n = 10 per group). m – p Percentage of m CD8 + T cells ( n = 10 per group), n NK cells ( n = 10 per group), o GzmB + CD8 + T cells ( n = 7 per group), and p GzmB + NK cells ( n = 7 per group) in IgG control and anti-TIGIT-treated epithelial cSCCs. q – s Percentage of GFP + EpCAM + and GFP + EpCAM − cancer cells in the indicated epithelial cSCCs ( n = 10 per group). All data are represented as the mean ± SD, and n values indicate independent tumors. P values are determined by two-way ANOVA test ( b , g , l ), one-way ANOVA with Dunnett’s multiple comparison test ( c – f , q ), and unpaired two-sided Student’s t -test ( h – k , m – p , r , s ). ns > 0.05: not significant. See Supplementary Fig. for the gating strategy ( c – f, h – k, m – s ). Source data are provided as a Source Data file.

Article Snippet: When tumors generated reached a volume of 65 mm 3 (5 × 5 mm), mice were randomly assigned to a control or ICB treatment group and treated intraperitoneally three times per week with a 200 μg/dose of mouse IgG2b isotype control (clone MPC-11, BioXCell, BE0086), polyclonal rat IgG isotype control (BE0094), anti-PD-L1 (clone 10F.9G2, BioXCell, BE0101), anti-PD-1 (clone RMP1-14, BioXCell, BE0146), anti-CTLA-4 (clone UC10-4F10-11, BioXCell, BE0032), and anti-TIGIT (clone 1G9, BioXCell, BE0274) antibodies for 21–28 days.

Techniques: Control, Comparison

Journal: Nature Communications

Article Title: Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma

doi: 10.1038/s41467-024-49718-8

Figure Lengend Snippet: a Growth kinetics of IgG control, anti-PD-L1, and anti-PD-1-treated mesenchymal cSCCs ( n = 10 per group). b – e Percentage of b CD8 + T cells, c NK cells, d GzmB + CD8 + T cells, and e GzmB + NK cells in IgG control, anti-PD-L1, and anti-PD-1-treated mesenchymal cSCCs ( n = 10 per group). f , k Growth kinetics of IgG control, ( f ) anti-CTLA-4, anti-CTLA-4 + anti-CD8, and anti-CTLA-4 + anti-NK or ( k ) anti-TIGIT, anti-TIGIT + anti-CD8, and anti-TIGIT + anti-NK-treated mesenchymal cSCCs ( n = 10 per group). For better visualization, this experiment has been separated into two graphs in which the IgG control group is the same. g – j , l , m Percentage of g , l CD8 + T cells, h , m NK cells, i GzmB + CD8 + T cells, and j GzmB + NK cells in the indicated mesenchymal cSCCs ( n = 10 per group). n, o Percentage of GFP + EpCAM + and GFP + EpCAM − cancer cells in the indicated mesenchymal cSCCs ( n = 10 per group). All data are represented as the mean ± SD, and n values indicate independent tumors. P values are determined by two-way ANOVA test ( a , f , k ) and one-way ANOVA with Dunnett’s multiple comparison test ( b – e , g – j , l – o ). ns > 0.05: not significant. See Supplementary Fig. for the gating strategy ( b – e , g – j , l – o ). Source data are provided as a Source Data file.

Article Snippet: When tumors generated reached a volume of 65 mm 3 (5 × 5 mm), mice were randomly assigned to a control or ICB treatment group and treated intraperitoneally three times per week with a 200 μg/dose of mouse IgG2b isotype control (clone MPC-11, BioXCell, BE0086), polyclonal rat IgG isotype control (BE0094), anti-PD-L1 (clone 10F.9G2, BioXCell, BE0101), anti-PD-1 (clone RMP1-14, BioXCell, BE0146), anti-CTLA-4 (clone UC10-4F10-11, BioXCell, BE0032), and anti-TIGIT (clone 1G9, BioXCell, BE0274) antibodies for 21–28 days.

Techniques: Control, Comparison

Journal: Nature Communications

Article Title: Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma

doi: 10.1038/s41467-024-49718-8

Figure Lengend Snippet: a Growth kinetics of IgG control and anti-PD-L1-treated mixed cSCCs ( n = 8 per group). b – e Percentage of b CD8 + T cells ( n = 8), c NK cells ( n = 8), d GzmB + CD8 + T cells ( n = 6), and e GzmB + NK cells ( n = 6) in IgG control and anti-PD-L1-treated mixed cSCCs. f Growth kinetics of IgG control and anti-CTLA-4-treated mixed cSCCs ( n = 8 per group). g – j Percentage of g CD8 + T cells ( n = 8), h NK cells ( n = 8), i GzmB + CD8 + T cells ( n = 6), and j GzmB + NK cells ( n = 6) in IgG control and anti-CTLA-4-treated mixed cSCCs. k Growth kinetics of IgG control, anti-PD-L1, anti-TIGIT, and anti-PD-L1 + anti-TIGIT-treated mixed cSCCs ( n = 10 per group). l – o Percentage of l CD8 + T cells ( n = 10), m NK cells ( n = 10), n GzmB + CD8 + T cells ( n = 7), and o GzmB + NK cells ( n = 7) in the indicated mixed cSCCs. p – r Percentage of GFP + EpCAM + and GFP + EpCAM − cancer cells in the indicated mixed cSCCs (PD-L1 and CTLA-4 experiments: n = 8 per group; PD-L1/TIGIT experiment: n = 10 per group). All data are represented as the mean ± SD, and n values indicate independent tumors. P values are determined by two-way ANOVA test ( a , f , k ), unpaired two-sided Student’s t -test ( b – e , g – j , p , q ), and one-way ANOVA with Dunnett’s multiple comparison test ( l – o , r ). See Supplementary Fig. for the gating strategy ( b – e , g – j , l – r ). Source data are provided as a Source Data file.

Article Snippet: When tumors generated reached a volume of 65 mm 3 (5 × 5 mm), mice were randomly assigned to a control or ICB treatment group and treated intraperitoneally three times per week with a 200 μg/dose of mouse IgG2b isotype control (clone MPC-11, BioXCell, BE0086), polyclonal rat IgG isotype control (BE0094), anti-PD-L1 (clone 10F.9G2, BioXCell, BE0101), anti-PD-1 (clone RMP1-14, BioXCell, BE0146), anti-CTLA-4 (clone UC10-4F10-11, BioXCell, BE0032), and anti-TIGIT (clone 1G9, BioXCell, BE0274) antibodies for 21–28 days.

Techniques: Control, Comparison